Trials / Terminated
TerminatedNCT01075412
FLT PET Imaging for Cervical Cancer
'F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- University of Iowa · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Our primary hypothesis is that \[18F\]FLT PET can identify active bone marrow in addition to metabolically active tumor. This trial will use FLT-PET imaging to define areas of active bone marrow in the pelvis. The radiation plan is then designed to spare that area, in hopes of keeping the bone marrow active during therapy. Bone marrow and tumor activity will be monitored using a sequence of FLT PET scans during the course of chemotherapy and radiation therapy.
Detailed description
Subjects will undergo a total of up to 5 FLT PET scans. Subjects are randomized between two groups to reduce radiation exposure from the FLT PET scans. If bone marrow activity is not identified in one scan, further scans are cancelled until the 1-month follow up scan. This is not a randomization to compare therapeutic efficacy between two study arms. Data will be pooled for analysis as pre-specified in the study's statistical plan. Group 1 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 15 radiation treatments, and then 1 month after completing radiation therapy. Group 2 has FLT PET scans pretreatment, after 5 radiation treatments, after 10 radiation treatments, after 20 radiation treatments, and then 1 month after completing radiation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [F18]Fluorothymidine | FLT PET scan 5 mCi (+/- 10%) |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2016-03-03
- Completion
- 2016-04-11
- First posted
- 2010-02-25
- Last updated
- 2017-12-02
- Results posted
- 2017-12-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01075412. Inclusion in this directory is not an endorsement.